ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Servier terminates CTI cancer pact following clinical failure
February 28, 2019Servier has terminated its Pixuvri collaboration agreement with CTI BioPharma. The action comes seven months after the B-cell non-Hodgkin lymphoma drug failed a key clinical trial.... -
CTI BioPharma Corp. Restructures
December 17, 2018CTI BioPharma Corp. is restructuring in an effort to improve efficiencies and reduce costs. As part of the plan, workforce reductions have been implemented that impact approximately 50 percent -
CTI, Servier’s Pixuvri fails in post-marketing trial
July 16, 2018A late-stage trial of Servier and CTI BioPharma’s Pixuvri in combination with Roche's MabThera has failed to hit targets in B-cell non-Hodgkin lymphoma, putting its conditional approval in Europe in jeopardy. -
Servier and CTI BioPharma Expand Pixuvri Agreement
April 27, 2017Servier and CTI BioPharma announced that they agreed to expand their existing license and development collaboration agreement for Pixuvri.
Pharma Sources Insight January 2025
